Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease
Haemophilia · 2026-11-14
DOI: 10.1111/hae.70451 ↗At a glance
Übersichtsarbeit in Haemophilia, published online on 2026-11-14. Written by Nicole Charbel and 9 co-authors. Institution: Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. 43 references.
Abstract (original language)
Introduction
Haemophilia and von Willebrand disease (VWD) are inherited bleeding disorders requiring lifelong access to haemostatic therapies and coordinated multidisciplinary care. Lebanon's prolonged economic and healthcare crises have disrupted medication supply, financing, and access to specialized services, creating particular challenges for individuals with rare bleeding disorders.
Aim
To evaluate how Lebanon's prolonged economic and healthcare crises affected treatment access, care delivery, and health‐system support for patients with haemophilia and VWD.
Methods
We conducted a narrative review incorporating a retrospective descriptive analysis of aggregated data from the Lebanese Association for Haemophilia (LAH) beneficiary registry and programmatic records, complemented by World Federation of Hemophilia data and published literature. The principal longitudinal LAH dataset covered 2019–2023, with updated beneficiary‐registry data through 2026.
Results
The number of individuals recorded in the LAH beneficiary registry increased from 458 in 2019 to 547 in 2023 and reached 591 by June 2026. Reliance on humanitarian treatment support increased substantially during the crisis. Recorded donated‐product quantities rose from 873,262 units in 2019 to 4,002,211 in 2022, representing a 4.58‐fold increase (+358.3%), before declining to 2,459,558 in 2023. By 2026, LAH programmatic data indicated partial recovery in factor VIII and IX availability and expansion of non‐factor therapy, including emicizumab, although shortages persisted for selected VWD and rare bleeding‐disorder therapies.
Conclusion
Lebanon's overlapping crises substantially disrupted haemophilia and VWD care and increased reliance on LAH and humanitarian assistance. Although treatment availability has partially improved, important gaps remain. Sustainable progress will require reliable national financing and procurement, coordinated registry systems, and prospective clinical‐outcome monitoring.
Subjects
Author keywords
Authors and institutions
- Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
- University of Balamand Faculty of Medicine and Medical Sciences, Al-Koura, Lebanon.
- Lebanese Society for Haemophilia, Beirut, Lebanon.
- Faculty of Medicine, Saint George University of Beirut, Beirut, Lebanon.
Cite
APA
Charbel, N., Khoury, S. E., Baroudi, K., Hodroj, M. H., Inati, A., Sakr, S., Haddad, C., Samaha, H., Taher, A., & Noun, P. (2026). Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease. Haemophilia. https://doi.org/10.1111/hae.70451
Vancouver
Charbel N, Khoury SE, Baroudi K, Hodroj MH, Inati A, Sakr S, et al. Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease. Haemophilia. 2026. doi:10.1111/hae.70451
BibTeX
@article{Charbel2026,
author = {Charbel, Nicole and Khoury, Sacha El and Baroudi, Khaled and Hodroj, Mohammad Hassan and Inati, Adlette and Sakr, Solange and Haddad, Cesar and Samaha, Hanady and Taher, Ali and Noun, Peter},
title = {Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease},
journal = {Haemophilia},
year = {2026},
doi = {10.1111/hae.70451}
}
EUVIMED